Skip to main content

Annual Reports

For 100 years, CSL has earned a reputation as a passionate yet responsible organization that is driven to care for patients and deliver on its commitments. Today, our future has never looked brighter. We expect that emerging new innovations and support programs can provide unprecedented opportunities to improve patient wellbeing unlike any other time in history.

View archived annual reports

Key Business Performance and Highlights

CSL continues to deliver on its strategy, with an 9%# increase in total revenue. The strength of our results reflects the execution of our strategic plan and patient-focussed workforce.


CSL Growth Icon


  • Another strong year with revenue up 9%^ and reported net profit after tax of US$2,103 million, up 17% at constant currency (CC)^.

  • Our largest franchise, the immunoglobulin portfolio, performed extremely well, with PRIVIGEN® sales growing 20%^ and HIZENTRA® sales up 34%^.

  • Seqirus’ earnings before interest and taxes grew more than 70% this year underpinned by sales of new and differentiated products - FLUCELVAX® and FLUAD®.

CSL Efficiency Icon


  • Major capital projects underway at all manufacturing sites to support future demand.

  • 40 new plasma collection centres opened in the United States (US).

  • Strategic review of end-to-end supply logistics.

  • Strategic partnership with Thermo Fisher Scientific for lease of CSL’s Lengnau, Switzerland, biotech manufacturing facility.

  • Direct distribution transition in China now complete.

  • Underwent 401 regulatory inspections of our manufacturing facilities* with no impact to licences or operations.

CSL Influenza Icon


  • Total revenue up 11% at CC basis driven by our seasonal influenza vaccines, with a significant increase in demand for FLUAD®, Seqirus’ adjuvanted influenza vaccine for the elderly market and increased sales of
    FLUCELVAX® Quadrivalent influenza vaccine.

CSL Innovation Icon


  • Acquired Vitaeris to expedite the development of Clazakizumab – an anti-interleukin-6 monoclonal antibody for the treatment of chronic antibody-mediation rejection (or AMR) in kidney transplant recipients.

  • Agreement to acquire the late stage gene therapy candidate for the treatment of haemophilia B from uniQure.

  • Futility test for CSL112 was completed with the recommendation that the trial should continue (currently in Phase III for cardiovascular disease).

  • Achieved 29 product registrations or new indications in numerous countries.

CSL People Icon


  • CSL named in Best Employers for Diversity (Forbes).

  • Employee workforce up 7%, with 57% of our employee base female.

  • Achieved 76% employee engagement score, up 2.4 points on prior year.

CSL Shared Value Icon


  • US$8.8 billion distributed in supplier payments, employee wages and benefits, shareholder returns, government taxes and community contributions.

  • US$38.7 million in global community investment across our strategic areas of support.

^Constant currency removes the impact of exchange rate movements, facilitating comparability of operational performance. For further detail please refer to page 16.
*Does not include Ruide. Limited assurance by Ernst & Young.

More here on (Our Company > Corporate Responsibility)

Annual Report Archive

This archive features CSL Limited's Annual Reports between 2013 and 2019